Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + doxorubicin + nab-paclitaxel
- Development stage
- Phase 3
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
The combination of cyclophosphamide, doxorubicin, and nab-paclitaxel is a neoadjuvant chemotherapy regimen primarily investigated for the treatment of high-risk breast cancer subtypes, including locally advanced breast cancer (LABC), inflammatory breast cancer (IBC), and triple-negative breast cancer (TNBC). This regimen typically utilizes a sequential or concurrent administration strategy. Nab-paclitaxel, a nanoparticle albumin-bound formulation of paclitaxel, is employed as a solvent-free alternative to conventional taxanes to enhance intratumoral drug delivery via albumin-mediated transport mechanisms and to reduce solvent-related toxicities. The regimen combines the DNA-alkylating properties of cyclophosphamide, the topoisomerase II inhibition and DNA intercalation of doxorubicin, and the microtubule-stabilizing effects of nab-paclitaxel to induce pathologic complete response (pCR) in aggressive breast malignancies.
- Brand names
- Abraxane (for paclitaxel albumin-bound)Adriamycin (for doxorubicin)
- Other names
- AC-nPnP-ACnab-paclitaxel + ACnab-paclitaxel + doxorubicin + cyclophosphamide
02
Targets
DNATOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on cyclophosphamide + doxorubicin + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + doxorubicin + nab-paclitaxel.